TII
11.4.2022 13:18:04 CEST | Business Wire | Press release
Technology Innovation Institute (TII), a global research center and applied research pillar of Abu Dhabi’s Advanced Technology Research Council, today announced the launch of NOOR, the world’s largest Arabic natural language processing (NLP) model to date.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220411005085/en/
TII’s team of advanced researchers and Artificial Intelligence (AI) specialists, has joined forces with LightOn, a technology company that unlocks extreme-scale machine intelligence for businesses, to transform the Arabic NLP model. The NOOR model has the capability to carry out tasks beyond the domain of language - offering end-to-end pipeline high quality data, including crawling, filtering, and curation at scale. The model facilitates extreme-scale distributed training and serving – to deliver applications with efficient inference and model specialization.
Dr. Ray O. Johnson, CEO, TII and ASPIRE, said: “With this development, we are well on track to enhance our research capabilities and credentials as well as elevate the status of Abu Dhabi and the UAE as a serious research ecosystem. Our expert teams have demonstrated yet again that this region can achieve breakthrough R&D outcomes to impact the world.”
Dr. Ebtesam Almazrouei, Director, AI Cross-Center Unit, TII, said: “Large language models have taken the world of natural language processing by storm, and we are proud to introduce this cutting-edge model with 10 billion parameters - the world’s largest Arabic NLP model. The uniquely large Arabic dataset collected to train the model is the result of months of work that included curating, scrapping, and filtering of varied sources. A special thank you to the entire team that worked on this project to make NOOR the go-to exploration model in Arabic for academicians and businesses everywhere.”
Speaking on the launch, Prof. Mérouane Debbah, Chief Researcher, Digital Science Research Center and AI Cross-Center Unit, TII, said: “With NOOR, TII has expanded the scope of the modern standard Arabic model by leveraging know-how in large language models to build cross-disciplinary, cutting-edge expertise in this new generation of AI research.”
To curate the world’s largest high-quality cross-domain Arabic datasets, NOOR’s unique dataset of more than 30 billion words combines web data with books, poetry, news articles, and technical information to significantly widen the applicability of the model.
Dr. Ebtesam Almazrouei said the NOOR model is based on the popular Transformer architecture. As a decoder-only model, similar in structure to GPT-3, it is programmed to tackle generative tasks with architecture upgraded to reflect the latest developments in the world of machine learning, including improvements such as better positional embeddings. To help ensure quality at scale in the NOOR dataset, the TII team designed an automated filtering pipeline based on machine learning techniques. These tools identify text like quality references and safeguard the model from exposure to spam content.
Leveraging state-of-the-art 3D parallelism, NOOR was trained on a High-Performance Computing resource with 128 A100 GPUs, allowing for the distribution of computations and ensuring efficient use of the available hardware resources.
The Director of the AI Cross-Center Unit noted that this was only the first step in the Unit’s efforts to contribute to the wider UAE Strategy for Artificial Intelligence.
Named for the Arabic word "light", the model has been so called to establish the correlation of the Arabic language model to enlightening the mind.
About Technology Innovation Institute (TII)
For more information, visit www.tii.ae
*Source: AETOSWire
View source version on businesswire.com: https://www.businesswire.com/news/home/20220411005085/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
